SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

X4 Pharmaceuticals, Inc. – ‘10-K’ for 12/31/23 – ‘EX-97.1’

On:  Thursday, 3/21/24, at 5:08pm ET   ·   For:  12/31/23   ·   Accession #:  1628280-24-12578   ·   File #:  1-38295

Previous ‘10-K’:  ‘10-K’ on 3/21/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   28 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/21/24  X4 Pharmaceuticals, Inc.          10-K       12/31/23   93:9.5M                                   Workiva Inc Wde… FA01/FA

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.97M 
 2: EX-10.37    Material Contract                                   HTML     33K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML     27K 
 7: EX-97.1     Clawback Policy re: Recovery of Erroneously         HTML     49K 
                Awarded Compensation                                             
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     31K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     31K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     28K 
13: R1          Cover                                               HTML     95K 
14: R2          Audit Information                                   HTML     32K 
15: R3          Consolidated Balance Sheets                         HTML    124K 
16: R4          Consolidated Balance Sheets (Parenthetical)         HTML     37K 
17: R5          Consolidated Statements of Operations and           HTML    104K 
                Comprehensive Loss                                               
18: R6          Consolidated Statements of Convertible Preferred    HTML    117K 
                Stock, Redeemable Common Stock and Stockholders'                 
                Equity (Deficit)                                                 
19: R7          Consolidated Statements of Cash Flows               HTML    120K 
20: R8          Nature of the Business and Basis of Presentation    HTML     37K 
21: R9          Summary of Significant Accounting Policies          HTML     88K 
22: R10         License, Collaboration, and Funding Agreements      HTML     47K 
23: R11         Fair Value of Financial Assets and Liabilities      HTML    129K 
24: R12         Property and Equipment, Net                         HTML     40K 
25: R13         Accrued Expenses                                    HTML     37K 
26: R14         Long-Term Debt                                      HTML     57K 
27: R15         Leases                                              HTML     56K 
28: R16         Commitment and Contingencies                        HTML     33K 
29: R17         Preferred and Common Stock Warrants                 HTML     81K 
30: R18         Common Stock, Redeemable Common Stock and           HTML     48K 
                Convertible Preferred Stock (converted to Common                 
                Stock)                                                           
31: R19         Stock-Based Compensation                            HTML     87K 
32: R20         Income Taxes                                        HTML     89K 
33: R21         Net Loss per Share                                  HTML     52K 
34: R22         Loss on Transfer of Nonfinancial Assets             HTML     31K 
35: R23         Summary of Significant Accounting Policies          HTML    117K 
                (Policies)                                                       
36: R24         Summary of Significant Accounting Policies          HTML     55K 
                (Tables)                                                         
37: R25         Fair Value of Financial Assets and Liabilities      HTML    137K 
                (Tables)                                                         
38: R26         Property and Equipment, Net (Tables)                HTML     39K 
39: R27         Accrued Expenses (Tables)                           HTML     37K 
40: R28         Long-Term Debt (Tables)                             HTML     52K 
41: R29         Leases (Tables)                                     HTML     55K 
42: R30         Preferred and Common Stock Warrants (Tables)        HTML     78K 
43: R31         Stock-Based Compensation (Tables)                   HTML     75K 
44: R32         Income Taxes (Tables)                               HTML     88K 
45: R33         Net Loss per Share (Tables)                         HTML     52K 
46: R34         Nature of the Business and Basis of Presentation    HTML     56K 
                (Details)                                                        
47: R35         Summary of Significant Accounting Policies -        HTML     46K 
                Schedule of Restricted Cash (Details)                            
48: R36         Summary of Significant Accounting Policies -        HTML     39K 
                Schedule of Cash, Cash Equivalents and Restricted                
                Cash (Details)                                                   
49: R37         Summary of Significant Accounting Policies -        HTML     40K 
                Schedule of Property, Plant and Equipment                        
                (Details)                                                        
50: R38         Summary of Significant Policies - Additional        HTML     38K 
                Information (Details)                                            
51: R39         License, Collaboration, and Funding Agreements -    HTML     54K 
                Genzyme Agreement (Details)                                      
52: R40         License, Collaboration, and Funding Agreements -    HTML     39K 
                Georgetown Agreement (Details)                                   
53: R41         License, Collaboration, and Funding Agreements -    HTML     47K 
                Beth Israel Deaconess Medical Center Agreements                  
                (Details)                                                        
54: R42         License, Collaboration, and Funding Agreements -    HTML     41K 
                Research and Development Incentive Program                       
                (Details)                                                        
55: R43         License, Collaboration, and Funding Agreements      HTML     30K 
                (Details)                                                        
56: R44         Fair Value of Financial Assets and Liabilities -    HTML     74K 
                Measured on a Recurring Basis (Details)                          
57: R45         Fair Value of Financial Assets and Liabilities -    HTML     45K 
                Debt Securities Available-for-Sale (Details)                     
58: R46         Fair Value of Financial Assets and Liabilities -    HTML     53K 
                Narrative (Details)                                              
59: R47         Fair Value of Financial Assets and Liabilities      HTML     55K 
                -Aggregate Fair Value of Warrant and Derivative                  
                Liabilities (Details)                                            
60: R48         Fair Value of Financial Assets and Liabilities -    HTML     50K 
                Assumptions (Details)                                            
61: R49         Fair Value of Financial Assets and Liabilities -    HTML     42K 
                Goodwill Rollforward (Details)                                   
62: R50         Property and Equipment, Net (Details)               HTML     49K 
63: R51         Accrued Expenses (Details)                          HTML     39K 
64: R52         Long-Term Debt - Schedule of Long-Term Debt         HTML     41K 
                (Details)                                                        
65: R53         Long-Term Debt - Narrative (Details)                HTML     63K 
66: R54         Long-Term Debt - Hercules Loan Agreements           HTML     35K 
                (Details)                                                        
67: R55         Long-Term Debt - Future Principal Payments          HTML     37K 
                (Details)                                                        
68: R56         Leases (Details)                                    HTML     79K 
69: R57         Leases - Schedule of Components of Lease Expense    HTML     47K 
                (Details)                                                        
70: R58         Leases - Schedule of Maturities of Lease            HTML     44K 
                Liabilities (Detail)                                             
71: R59         Preferred and Common Stock Warrants - Additional    HTML     84K 
                Information (Details)                                            
72: R60         Preferred and Common Stock Warrants - Schedule of   HTML     50K 
                Outstanding Warrants (Detail)                                    
73: R61         Preferred and Common Stock Warrants - Summary of    HTML    103K 
                Outstanding Warrants to Purchase Shares of Common                
                Stock (Details)                                                  
74: R62         Common Stock, Redeemable Common Stock and           HTML    192K 
                Convertible Preferred Stock (converted to Common                 
                Stock) - Additional Information (Details)                        
75: R63         Stock-Based Compensation - Additional Information   HTML     94K 
                (Details)                                                        
76: R64         Stock-Based Compensation - Summary of Stock Option  HTML     79K 
                Activity (Detail)                                                
77: R65         Stock-Based Compensation - Restricted Stock Units   HTML     38K 
                (Details)                                                        
78: R66         Stock-Based Compensation - Summary of Stock-Based   HTML     42K 
                Compensation Expense Classification (Details)                    
79: R67         Stock-Based Compensation - Stock Option Valuation   HTML     52K 
                (Details)                                                        
80: R68         Income Taxes - Schedule of Income Loss Before       HTML     37K 
                Income Taxes (Details)                                           
81: R69         Income Taxes - Reconciliation of Effective Income   HTML     44K 
                Tax Rate (Details)                                               
82: R70         Income Taxes - Deferred Income Tax Asset (Details)  HTML     50K 
83: R71         Income Taxes - Narrative (Details)                  HTML     48K 
84: R72         Income Taxes - Deferred Tax Valuation Allowance     HTML     33K 
                (Details)                                                        
85: R73         Income Taxes (Details)                              HTML     31K 
86: R74         Net Loss per Share - Summary of Basic and Diluted   HTML     65K 
                Net loss per Share Attributable to Common                        
                Stockholders (Details)                                           
87: R75         Net Loss per Share - Additional Information         HTML     39K 
                (Details)                                                        
88: R76         Net Loss per Share - Schedule of Anti-dilutive      HTML     38K 
                Securities Excluded from Computation of Diluted                  
                Net Loss per Share Attributable to Common                        
                Stockholders (Details)                                           
90: XML         IDEA XML File -- Filing Summary                      XML    170K 
93: XML         XBRL Instance -- xfor-20231231_htm                   XML   1.90M 
89: EXCEL       IDEA Workbook of Financial Report Info              XLSX    199K 
 9: EX-101.CAL  XBRL Calculations -- xfor-20231231_cal               XML    190K 
10: EX-101.DEF  XBRL Definitions -- xfor-20231231_def                XML    760K 
11: EX-101.LAB  XBRL Labels -- xfor-20231231_lab                     XML   1.70M 
12: EX-101.PRE  XBRL Presentations -- xfor-20231231_pre              XML   1.22M 
 8: EX-101.SCH  XBRL Schema -- xfor-20231231                         XSD    212K 
91: JSON        XBRL Instance as JSON Data -- MetaLinks              523±   804K 
92: ZIP         XBRL Zipped Folder -- 0001628280-24-012578-xbrl      Zip    586K 


‘EX-97.1’   —   Clawback Policy re: Recovery of Erroneously Awarded Compensation


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:   C: 
  Document  
                                                                                    
EX 97.1
X4 Pharmaceuticals, Inc.
Incentive Compensation Recoupment Policy
1.Introduction
The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of X4 PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recoverable Incentive Compensation that is received by Covered Officers of the Company under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 3 below.
This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder (“Rule 10D-1”) and Nasdaq Listing Rule 5608 (the “Listing Standards”).
2.Effective Date
This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the “Effective Date”). Incentive Compensation is deemed “received” in the Company’s fiscal period in which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period.
3.Definitions
Accounting Restatement” means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.
Accounting Restatement Date” means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.
Administrator” means the Compensation Committee or, in the absence of such committee, the Board.
Code” means the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.
Covered Officer” means each current and former Executive Officer.
Exchange” means the Nasdaq Stock Market.
Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended.
Executive Officer” means the Company’s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs



similar policy-making functions for the Company. Executive officers of the Company’s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy-making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified pursuant to Item 401(b) of Regulation S-K promulgated under the Exchange Act.
Financial Reporting Measures” means measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measures derived wholly or in part from such measures, including Company stock price and total stockholder return (“TSR”). A measure need not be presented in the Company’s financial statements or included in a filing with the SEC in order to be a Financial Reporting Measure.
Incentive Compensation” means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.
Lookback Period” means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company’s fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date.
Recoverable Incentive Compensation” means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (i.e., on a gross basis without regard to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Administrator will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards.
SEC” means the U.S. Securities and Exchange Commission.
4.Recoupment
(1)Applicability of Policy. This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv) during the Lookback Period.
(2)Recoupment Generally. Pursuant to the provisions of this Policy, if there is an Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation Committee, or, if such committee does not consist solely of independent directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company’s obligation to recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed.
(3)Impracticability of Recovery. Recoupment may be determined to be impracticable if, and only if:
2



(a)the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange in accordance with the Listing Standards; or
(b)recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder.
(4)Sources of Recoupment. To the extent permitted by applicable law, the Administrator shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Administrator may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date: (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid); (iii) cancelling or offsetting against any planned future cash or equity-based awards; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, e.g., base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. The Administrator need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation.
(5)No Indemnification of Covered Officers. Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company’s certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy.
(6)Indemnification of Administrator. Any members of the Administrator, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be indemnified by the Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.
(7)No “Good Reason” for Covered Officers. Any action by the Company to recoup or any recoupment of Recoverable Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i) “good reason” for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii) to constitute a breach of a contract or other arrangement to which such Covered Officer is party.
5.Administration
Except as specifically set forth herein, this Policy shall be administered by the Administrator. The Administrator shall have full and final authority to make any and all determinations required under this Policy. Any determination by the Administrator with respect to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual covered by this Policy. In carrying out the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee’s responsibility and authority. Subject to applicable
3



law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions that the Administrator, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).
6.Severability
If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.
7.No Impairment of Other Remedies
Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer’s obligations to the Company, including, without limitation, termination of employment and/or institution of civil proceedings. This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 (“SOX 304”) that are applicable to the Company’s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and/or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time; provided, however, that compensation recouped pursuant to this Policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and/or similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law.
8.Amendment; Termination
The Administrator may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time in its sole discretion. The Administrator shall amend this Policy as it deems necessary to comply with applicable law or any Listing Standard.
9.Successors
This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and/or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives.
10.    Required Filings
    The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required by the SEC.
* * * * *
4



X4 Pharmaceuticals, Inc.
Incentive Compensation Recoupment Policy
Form of Executive Acknowledgment

I, the undersigned, agree and acknowledge that I am bound by, and subject to, the X4 PHARMACEUTICALS, INC. Incentive Compensation Recoupment Policy, as may be amended, restated, supplemented or otherwise modified from time to time (the “Policy”). In the event of any inconsistency between the Policy and the terms of any employment agreement, offer letter or other individual agreement with X4 PHARMACEUTICALS, INC. (the “Company”) to which I am a party, or the terms of any compensation plan, program or agreement, whether or not written, under which any compensation has been granted, awarded, earned or paid to me, the terms of the Policy shall govern.
In the event that the Administrator (as defined in the Policy) determines that any compensation granted, awarded, earned or paid to me must be forfeited or reimbursed to the Company pursuant to the Policy, I will promptly take any action necessary to effectuate such forfeiture and/or reimbursement. I further agree and acknowledge that I am not entitled to indemnification, and hereby waive any right to advancement of expenses, in connection with any enforcement of the Policy by the Company.

Agreed and Acknowledged:

    
Name:     
Title:     
Date:     




Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/21/248-K
For Period end:12/31/23
10/2/23
 List all Filings 


28 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/09/23  X4 Pharmaceuticals, Inc.          10-Q        9/30/23   75:6.9M                                   Workiva Inc Wde… FA01/FA
 8/10/23  X4 Pharmaceuticals, Inc.          10-Q        6/30/23   76:7.4M                                   Workiva Inc Wde… FA01/FA
 5/16/23  X4 Pharmaceuticals, Inc.          8-K:1,3,7,8 5/15/23   16:4.6M                                   Workiva Inc Wde… FA01/FA
 3/21/23  X4 Pharmaceuticals, Inc.          10-K       12/31/22   96:34M                                    Workiva Inc Wde… FA01/FA
12/09/22  X4 Pharmaceuticals, Inc.          8-K:1,8    12/06/22   16:953K                                   Workiva Inc Wde… FA01/FA
11/09/22  X4 Pharmaceuticals, Inc.          8-K:5      11/07/22   11:265K                                   Workiva Inc Wde… FA01/FA
 9/01/22  X4 Pharmaceuticals, Inc.          8-K:3,5     9/01/22   11:2.9M                                   Workiva Inc Wde… FA01/FA
 7/01/22  X4 Pharmaceuticals, Inc.          8-K:1,2,3,8 6/30/22   16:1M                                     Workiva Inc Wde… FA01/FA
 3/17/22  X4 Pharmaceuticals, Inc.          10-K       12/31/21  100:10M                                    Workiva Inc Wde… FA01/FA
 3/03/22  X4 Pharmaceuticals, Inc.          8-K:1,3,8   3/03/22   13:744K                                   Workiva Inc Wde… FA01/FA
 1/14/22  X4 Pharmaceuticals, Inc.          8-K:1,9     1/14/22   13:727K                                   Workiva Inc Wde… FA01/FA
11/05/21  X4 Pharmaceuticals, Inc.          8-K:1,3    11/05/21   13:735K                                   Workiva Inc Wde… FA01/FA
 3/19/21  X4 Pharmaceuticals, Inc.          10-K       12/31/20  100:12M                                    Workiva Inc Wde… FA01/FA
 3/19/21  X4 Pharmaceuticals, Inc.          8-K:1,2,3,8 3/18/21   17:1M                                     Workiva Inc Wde… FA01/FA
 8/07/20  X4 Pharmaceuticals, Inc.          S-3                    8:1.3M                                   Donnelley … Solutions/FA
 6/10/20  X4 Pharmaceuticals, Inc.          S-8         6/10/20    5:331K                                   Workiva Inc Wde… FA01/FA
 5/07/20  X4 Pharmaceuticals, Inc.          10-Q        3/31/20   73:7.2M                                   Workiva Inc Wde… FA01/FA
 3/12/20  X4 Pharmaceuticals, Inc.          10-K       12/31/19  115:15M                                    Workiva Inc Wde… FA01/FA
11/27/19  X4 Pharmaceuticals, Inc.          8-K:1,8,9  11/25/19    7:474K                                   Donnelley … Solutions/FA
 6/19/19  X4 Pharmaceuticals, Inc.          8-K:5,9     6/17/19    7:265K                                   Donnelley … Solutions/FA
 5/13/19  X4 Pharmaceuticals, Inc.          8-K/A:9     3/11/19    5:543K                                   Donnelley … Solutions/FA
 4/15/19  X4 Pharmaceuticals, Inc.          8-K:1,8,9   4/12/19    6:455K                                   Donnelley … Solutions/FA
 4/03/19  X4 Pharmaceuticals, Inc.          8-K/A:9     3/11/19    5:912K                                   Donnelley … Solutions/FA
 3/13/19  X4 Pharmaceuticals, Inc.          8-K:2,3,5,8 3/11/19   22:2.6M                                   Donnelley … Solutions/FA
11/27/18  X4 Pharmaceuticals, Inc.          8-K:1,5,7,811/26/18   10:8.9M                                   Donnelley … Solutions/FA
11/20/17  X4 Pharmaceuticals, Inc.          8-K:5,9    11/20/17    3:176K                                   Donnelley … Solutions/FA
11/06/17  X4 Pharmaceuticals, Inc.          S-1/A                  8:4.3M                                   Donnelley … Solutions/FA
10/20/17  X4 Pharmaceuticals, Inc.          S-1                   49:9.2M                                   Donnelley … Solutions/FA
Top
Filing Submission 0001628280-24-012578   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., Apr. 29, 4:43:45.3pm ET